생체흡수성 혈관 스캐폴드 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)

Bioresorbable Vascular Scaffold Market (Product Type: Everolimus-eluting Device, Novolimus-eluting Device, Sirolimus-eluting Device, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

US $ 5,795 ￦ 8,182,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,795 ￦ 12,418,000

PDF (Multi-user License)

PDF 보고서를 동일 부서 5명이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste가 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,795 ￦ 16,654,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

생체흡수성 혈관 스캐폴드 시장 - 보고서의 범위

TMR의 세계 생체흡수성 혈관 스캐폴드 시장에 대한 연구 보고서는 2023년부터 2031년까지의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 추세와 기회도 조사하여 2023년을 기준 연도로, 2031년을 예측 연도로 삼았습니다, 2017-2031년간 세계 시장 수익을 제공합니다. 또한 2023-2031년간 세계 시장의 복합 연간 성장률(CAGR%)도 제공합니다.

란다. 랍니다. 이 보고서는 광범위한 조사를 통해 작성되었으며, 1차 조사에서는 분석가들이 KOL(Key Opinion Leader), 업계 리더 및 오피니언 제조업체를 인터뷰하여 주요 조사 활동의 대부분을 수행했으며, 2차 조사에서는 주요 기업의 제품 문헌, 연례 보고서, 보도 자료 및 관련 문서에 대한 참조를 통해 생체흡수성 혈관 스캐폴드 시장을 파악했습니다.

이 보고서는 세계 생체흡수성 혈관 스캐폴드 시장 경쟁 구도를 자세히 분석합니다. 세계 생체흡수성 혈관 스캐폴드 시장에서 활동하는 주요 기업이 식별되며, 이들 각각은 다양한 속성 측면에서 프로파일링됩니다. 기업 프로파일, 재무 상태, 최근 동향 및 SWOT는 이 보고서에 소개된 세계 생체흡수성 혈관 스캐폴드 시장 기업의 속성입니다.

목차

제1장 서문

제2장 가정과 조사 방법

제3장 주요 요약 : 세계 시장

제4장 시장 개요

• 서론
• 개요
• 시장 역학
• 세계 시장 분석과 예측, 2017-2031년

제5장 주요 인사이트

• 기술 진보
• 질병 발생률과 유병률
• 규제 분석
• COVID-19의 영향 분석

제6장 세계 시장 분석과 예측 : 제품 유형별

• 서론과 정의
• 주요 발견과 개발
• 매출 예측 : 제품 유형별, 2017-2031
  • Everolimus-eluting Device
  • Novolimus-eluting Device
  • Sirolimus-eluting Device
  • 기타(Rapamycin 등)
• 시장 매력 분석 : 제품 유형별

제7장 세계 시장 분석과 예측 : 질환 유형별

• 서론과 정의
• 주요 발견과 개발
• 매출 예측 : 질환별, 2017년-2031년
  • 관상동맥 질환
  • 말초동맥 질환
• 시장 매력 분석 : 질환별

제8장 세계 시장 분석과 예측 : 재료 유형별

• 서론과 정의
• 주요 발견과 개발
• 매출 예측 : 소재별, 2017년-2031년
  • Poly-L-Lactic Acid (PLLA)
  • Tyrosine-derived Polycarbonate
  • 기타(Polydioxanone 등)
• 시장 매력 분석 : 소재별

제9장 세계 시장 분석과 예측 : 최종사용자별

• 서론과 정의
• 주요 발견과 개발
• 매출 예측 : 최종사용자별, 2017년-2031년
  • 병원
  • 외래수술센터(ASC)
  • 심장 카테터 검사실
  • 기타(연구 등)
• 시장 매력 분석 : 최종사용자별

제10장 세계 시장 분석과 예측 : 지역별

• 주요 조사 결과
• 매출 예측 : 지역별
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카
• 시장 매력 분석 : 지역별

제11장 북미 시장 분석과 예측

제12장 유럽 시장 분석과 예측

제13장 아시아태평양 시장 분석과 예측

제14장 라틴아메리카 시장 분석과 예측

제15장 중동 및 아프리카 시장 분석과 예측

제16장 경쟁 구도

• 시장 기업 - 경쟁 매트릭스(기업 Tier 및 규모별)
• 기업별 시장 점유율 분석(2021)
• 기업 개요
  • Kyoto Medical Planning Co., Ltd.
  • BIOTRONIK Group of Companies
  • REVA Medical
  • Elixir Medical
  • Arterius
  • Meril Life Sciences Pvt. Ltd
  • S3V Vascular Technologies
  • Zorion medical
  • Medtronic(development phase)

LSH

영문 목차

영문목차

Bioresorbable Vascular Scaffold Market - Scope of Report

TMR's report on the global Bioresorbable Vascular Scaffold market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Bioresorbable Vascular Scaffold market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Bioresorbable Vascular Scaffold market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Bioresorbable Vascular Scaffold market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Bioresorbable Vascular Scaffold market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Bioresorbable Vascular Scaffold market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Bioresorbable Vascular Scaffold market.

The report delves into the competitive landscape of the global Bioresorbable Vascular Scaffold market. Key players operating in the global Bioresorbable Vascular Scaffold market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Bioresorbable Vascular Scaffold market profiled in this report.

Key Questions Answered in Global Bioresorbable Vascular Scaffold Market Report:

• What is the sales/revenue generated by Bioresorbable Vascular Scaffold across all regions during the forecast period?
• What are the opportunities in the global Bioresorbable Vascular Scaffold market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Bioresorbable Vascular Scaffold Market - Research Objectives and Research Approach

The comprehensive report on the global Bioresorbable Vascular Scaffold market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Bioresorbable Vascular Scaffold market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Bioresorbable Vascular Scaffold market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Bioresorbable Vascular Scaffold Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Product Definition
  • 4.1.2. Industry Evolution / Development
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Bioresorbable Vascular Scaffold Market Analysis and Forecasts, 2017 - 2031

5. Key Insights

• 5.1. Technological Advancement
• 5.2. Disease Incidence and Prevalence
• 5.3. Regulatory Analysis
• 5.4. COVID-19 Impact Analysis

6. Global Bioresorbable Vascular Scaffold Market Analysis and Forecasts, by Product Type

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast, by Product Type, 2017 - 2031
  • 6.3.1. Everolimus-eluting Device
  • 6.3.2. Novolimus-eluting Device
  • 6.3.3. Sirolimus-eluting Device
  • 6.3.4. Others (Rapamycin, etc.)
• 6.4. Market Attractiveness Analysis, By Product Type

7. Global Bioresorbable Vascular Scaffold Market Analysis and Forecasts, by Disease Type

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast, by Disease Type, 2017 - 2031
  • 7.3.1. Coronary Artery Disease
  • 7.3.2. Peripheral Artery Disease
• 7.4. Market Attractiveness Analysis, By Disease Type

8. Global Bioresorbable Vascular Scaffold Market Analysis and Forecasts, by Material Type

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast, by Material Type, 2017 - 2031
  • 8.3.1. Poly-L-Lactic Acid (PLLA)
  • 8.3.2. Tyrosine-derived Polycarbonate
  • 8.3.3. Others (Polydioxanone, etc.)
• 8.4. Market Attractiveness Analysis, By Material Type

9. Global Bioresorbable Vascular Scaffold Market Analysis and Forecasts, by End-user

• 9.1. Introduction & Definition
• 9.2. Key Findings / Developments
• 9.3. Market Value Forecast, by End-user, 2017 - 2031
  • 9.3.1. Hospital
  • 9.3.2. Ambulatory Surgical Center
  • 9.3.3. Cardiac Catheterization Lab
  • 9.3.4. Others (Research Institute, etc.)
• 9.4. Market Attractiveness Analysis, By End-user

10. Global Bioresorbable Vascular Scaffold Market Analysis and Forecasts, by Region

• 10.1. Key Findings
• 10.2. Market Value Forecast, by Region
  • 10.2.1. North America
  • 10.2.2. Europe
  • 10.2.3. Asia Pacific
  • 10.2.4. Latin America
  • 10.2.5. Middle East & Africa
• 10.3. Market Attractiveness Analysis, By Region

11. North America Bioresorbable Vascular Scaffold Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast, by Product Type, 2017 - 2031
  • 11.2.1. Everolimus-eluting Device
  • 11.2.2. Novolimus-eluting Device
  • 11.2.3. Sirolimus-eluting Device
  • 11.2.4. Others (Rapamycin, etc.)
• 11.3. Market Value Forecast, by Disease Type, 2017 - 2031
  • 11.3.1. Coronary Artery Disease
  • 11.3.2. Peripheral Artery Disease
• 11.4. Market Value Forecast, by Material Type, 2017 - 2031
  • 11.4.1. Poly-L-Lactic Acid (PLLA)
  • 11.4.2. Tyrosine-derived Polycarbonate
  • 11.4.3. Others (Polydioxanone, etc.)
• 11.5. Market Value Forecast, by End-user, 2017 - 2031
  • 11.5.1. Hospital
  • 11.5.2. Ambulatory Surgical Center
  • 11.5.3. Cardiac Catheterization Lab
  • 11.5.4. Others (Research Institute, etc.)
• 11.6. Market Value Forecast, by Country, 2017 - 2031
  • 11.6.1. U.S.
  • 11.6.2. Canada
• 11.7. Market Attractiveness Analysis
  • 11.7.1. By Product Type
  • 11.7.2. By Disease Type
  • 11.7.3. By Material Type
  • 11.7.4. By End-user
  • 11.7.5. By Country

12. Europe Bioresorbable Vascular Scaffold Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by Product Type, 2017 - 2031
  • 12.2.1. Everolimus-eluting Device
  • 12.2.2. Novolimus-eluting Device
  • 12.2.3. Sirolimus-eluting Device
  • 12.2.4. Others (Rapamycin, etc.)
• 12.3. Market Value Forecast, by Disease Type, 2017 - 2031
  • 12.3.1. Coronary Artery Disease
  • 12.3.2. Peripheral Artery Disease
• 12.4. Market Value Forecast, by Material Type, 2017 - 2031
  • 12.4.1. Poly-L-Lactic Acid (PLLA)
  • 12.4.2. Tyrosine-derived Polycarbonate
  • 12.4.3. Others (Polydioxanone, etc.)
• 12.5. Market Value Forecast, by End-user, 2017 - 2031
  • 12.5.1. Hospital
  • 12.5.2. Ambulatory Surgical Center
  • 12.5.3. Cardiac Catheterization Lab
  • 12.5.4. Others (Research Institute, etc.)
• 12.6. Market Value Forecast, by Country/Sub-region, 2017 - 2031
  • 12.6.1. Germany
  • 12.6.2. U.K.
  • 12.6.3. France
  • 12.6.4. Spain
  • 12.6.5. Italy
  • 12.6.6. Rest of Europe
• 12.7. Market Attractiveness Analysis
  • 12.7.1. By Product Type
  • 12.7.2. By Disease Type
  • 12.7.3. By Material Type
  • 12.7.4. By End-user
  • 12.7.5. By Country/Sub-region

13. Asia Pacific Bioresorbable Vascular Scaffold Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Product Type, 2017 - 2031
  • 13.2.1. Everolimus-eluting Device
  • 13.2.2. Novolimus-eluting Device
  • 13.2.3. Sirolimus-eluting Device
  • 13.2.4. Others (Rapamycin, etc.)
• 13.3. Market Value Forecast, by Disease Type, 2017 - 2031
  • 13.3.1. Coronary Artery Disease
  • 13.3.2. Peripheral Artery Disease
• 13.4. Market Value Forecast, by Material Type, 2017 - 2031
  • 13.4.1. Poly-L-Lactic Acid (PLLA)
  • 13.4.2. Tyrosine-derived Polycarbonate
  • 13.4.3. Others (Polydioxanone, etc.)
• 13.5. Market Value Forecast, by End-user, 2017 - 2031
  • 13.5.1. Hospital
  • 13.5.2. Ambulatory Surgical Center
  • 13.5.3. Cardiac Catheterization Lab
  • 13.5.4. Others (Research Institute, etc.)
• 13.6. Market Value Forecast, by Country/Sub-region, 2017 - 2031
  • 13.6.1. China
  • 13.6.2. Japan
  • 13.6.3. India
  • 13.6.4. Australia & New Zealand
  • 13.6.5. Rest of Asia Pacific
• 13.7. Market Attractiveness Analysis
  • 13.7.1. By Product Type
  • 13.7.2. By Disease Type
  • 13.7.3. By Material Type
  • 13.7.4. By End-user
  • 13.7.5. By Country/Sub-region

14. Latin America Bioresorbable Vascular Scaffold Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast, by Product Type, 2017 - 2031
  • 14.2.1. Everolimus-eluting Device
  • 14.2.2. Novolimus-eluting Device
  • 14.2.3. Sirolimus-eluting Device
  • 14.2.4. Others (Rapamycin, etc.)
• 14.3. Market Value Forecast, by Disease Type, 2017 - 2031
  • 14.3.1. Coronary Artery Disease
  • 14.3.2. Peripheral Artery Disease
• 14.4. Market Value Forecast, by Material Type, 2017 - 2031
  • 14.4.1. Poly-L-Lactic Acid (PLLA)
  • 14.4.2. Tyrosine-derived Polycarbonate
  • 14.4.3. Others (Polydioxanone, etc.)
• 14.5. Market Value Forecast, by End-user, 2017 - 2031
  • 14.5.1. Hospital
  • 14.5.2. Ambulatory Surgical Center
  • 14.5.3. Cardiac Catheterization Lab
  • 14.5.4. Others (Research Institute, etc.)
• 14.6. Market Value Forecast, by Country/Sub-region, 2017 - 2031
  • 14.6.1. Brazil
  • 14.6.2. Mexico
  • 14.6.3. Rest of Latin America
• 14.7. Market Attractiveness Analysis
  • 14.7.1. By Product Type
  • 14.7.2. By Disease Type
  • 14.7.3. By Material Type
  • 14.7.4. By End-user
  • 14.7.5. By Country/Sub-region

15. Middle East & Africa Bioresorbable Vascular Scaffold Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast, by Product Type, 2017 - 2031
  • 15.2.1. Everolimus-eluting Device
  • 15.2.2. Novolimus-eluting Device
  • 15.2.3. Sirolimus-eluting Device
  • 15.2.4. Others (Rapamycin, etc.)
• 15.3. Market Value Forecast, by Disease Type, 2017 - 2031
  • 15.3.1. Coronary Artery Disease
  • 15.3.2. Peripheral Artery Disease
• 15.4. Market Value Forecast, by Material Type, 2017 - 2031
  • 15.4.1. Poly-L-Lactic Acid (PLLA)
  • 15.4.2. Tyrosine-derived Polycarbonate
  • 15.4.3. Others (Polydioxanone, etc.)
• 15.5. Market Value Forecast, by End-user, 2017 - 2031
  • 15.5.1. Hospital
  • 15.5.2. Ambulatory Surgical Center
  • 15.5.3. Cardiac Catheterization Lab
  • 15.5.4. Others (Research Institute, etc.)
• 15.6. Market Value Forecast, by Country/Sub-region, 2017 - 2031
  • 15.6.1. GCC Countries
  • 15.6.2. South Africa
  • 15.6.3. Rest of Middle East & Africa
• 15.7. Market Attractiveness Analysis
  • 15.7.1. By Product Type
  • 15.7.2. By Disease Type
  • 15.7.3. By Material Type
  • 15.7.4. By End-user
  • 15.7.5. By Country/Sub-region

16. Competition Landscape

• 16.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 16.2. Market Share Analysis By Company (2021)
• 16.3. Company Profiles
  • 16.3.1. Kyoto Medical Planning Co., Ltd.
    • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.1.2. Test Type Portfolio
    • 16.3.1.3. Financial Overview
    • 16.3.1.4. SWOT Analysis
    • 16.3.1.5. Strategic Overview
  • 16.3.2. BIOTRONIK Group of Companies
    • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.2.2. Test Type Portfolio
    • 16.3.2.3. Financial Overview
    • 16.3.2.4. SWOT Analysis
    • 16.3.2.5. Strategic Overview
  • 16.3.3. REVA Medical
    • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.3.2. Test Type Portfolio
    • 16.3.3.3. Financial Overview
    • 16.3.3.4. SWOT Analysis
    • 16.3.3.5. Strategic Overview
  • 16.3.4. Elixir Medical
    • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.4.2. Test Type Portfolio
    • 16.3.4.3. Financial Overview
    • 16.3.4.4. SWOT Analysis
    • 16.3.4.5. Strategic Overview
  • 16.3.5. Arterius
    • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.5.2. Test Type Portfolio
    • 16.3.5.3. Financial Overview
    • 16.3.5.4. SWOT Analysis
    • 16.3.5.5. Strategic Overview
  • 16.3.6. Meril Life Sciences Pvt. Ltd
    • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.6.2. Test Type Portfolio
    • 16.3.6.3. Financial Overview
    • 16.3.6.4. SWOT Analysis
    • 16.3.6.5. Strategic Overview
  • 16.3.7. S3V Vascular Technologies
    • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.7.2. Test Type Portfolio
    • 16.3.7.3. Financial Overview
    • 16.3.7.4. SWOT Analysis
    • 16.3.7.5. Strategic Overview
  • 16.3.8. Zorion medical
    • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.8.2. Test Type Portfolio
    • 16.3.8.3. Financial Overview
    • 16.3.8.4. SWOT Analysis
    • 16.3.8.5. Strategic Overview
  • 16.3.9. Medtronic (development phase)
    • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.9.2. Test Type Portfolio
    • 16.3.9.3. Financial Overview
    • 16.3.9.4. SWOT Analysis
    • 16.3.9.5. Strategic Overview

관련자료